Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Antimicrobial agents and chemotherapy - 1 Jan 2015

Nayar Asha S, Dougherty Thomas J, Reck Folkert, Thresher Jason, Gao Ning, Shapiro Adam B, Ehmann David E

Abstract excerpt

In a previous report (T. J. Dougherty, A. Nayar, J. V. Newman, S. Hopkins, G. G. Stone, M. Johnstone, A. B. Shapiro, M. Cronin, F. Reck, and D. E. Ehmann, Antimicrob Agents Chemother 58:2657-2664, 2014), a novel bacterial type II topoisomerase inhibitor, NBTI 5463, with activity against Gram-negative pathogens was described. First-step resistance mutations in Pseudomonas aeruginosa arose exclusively in the nfxB...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Gyrase
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Escherichia coli Proteins

Share to Microbial Sensitivity Tests

Share to Morpholines

Share to Naphthyridines

Share to Pseudomonas aeruginosa

Share to Topoisomerase II Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25348539
DOI: 10.1128/AAC.04077-14
PMCID: PMC4291369

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.PMID 25348539Read ↗

Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. HydeSemantic proximity Read ↗

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitorsSemantic proximity Read ↗

Natural Alkaloid Berberine Activity against Pseudomonas aeruginosa MexXY-Mediated Aminoglycoside Resistance: In Silico and in Vitro StudiesSemantic proximity Read ↗

Mechanisms of action and resistance of older and newer fluoroquinolones.Semantic proximity Read ↗

Mechanism of action of and resistance to quinolones.Semantic proximity Read ↗

The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa.Semantic proximity Read ↗

Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.Semantic proximity Read ↗

Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.Semantic proximity Read ↗

Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.Semantic proximity Read ↗

Resistance to Antibiotics Mediated by Target AlterationsSemantic proximity Read ↗

In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.Semantic proximity Read ↗

A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.